An observational study in Notalgia Paresthetica, sponsored by Sisli Hamidiye Etfal Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-07-18.
Sponsored by Sisli Hamidiye Etfal Training and Research Hospital · Observational
Patients diagnosed with Notalgia paresthetica and who received neural therapy within the last year were retrospectively screened. In the evaluations before treatment and at the 3rd month after treatment; Numerical rating scale for pain, PainDETECT questionnaire for neuropathic pain, SF-12 for quality of life and 5-D itch scale for itch level were used.
2,373 studies on the registry are indexed under Back Pain; 284 are open to participants now.
This study's enrollment of 12 is below the median of 100 across 357 observational studies indexed under Back Pain.
Browse Back Pain studies →Sisli Hamidiye Etfal Training and Research Hospital is the lead sponsor of 110 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
30-60 years old patients with Notalgia Paresthetica
Exclusion Criteria:
The injection was prepared using a solution of lidocaine 2% and saline 0.9%. A 0.4% lidocaine solution was prepared by diluting 1 cc of lidocaine with 4 cc of saline.
Numeric Rating Scale for Pain
A scale between 0 and 10 was used to question the pain level.
Time frame: 12 weeks after treatment
PainDETECT Questionnaire for assessing Neuropathic pain
The questionnaire consists of 9 items and is completed by the patient (no clinical examination is required)\[1\]\[3\]. There are 7 weighted sensory descriptor items (never to very strongly) and 2 items relating to spatial and temporal pain characteristics\[3\]. A total score of 19 or more is indicative of likely neuropathic pain.
Time frame: 12 weeks after treatment
Short Form-12 for Quality of life
The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
Time frame: 12 weeks after treatment
5-D Itch Scale
The 5-D itch scale is a 5-domain disease-specific instrument evaluating the duration, degree (severity), direction (improving, unaltered or worsening), disability (impact on sleep, leisure/social, housework/errands and school/work activities) and distribution (body part affected)
Time frame: 12 weeks after treatment
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sisli Hamidiye Etfal Training and Research Hospital